Nature | Letter
Promoterless gene targeting without nucleases ameliorates haemophilia B in mice
- Journal name:
- Nature
- Year published:
- DOI:
- doi:10.1038/nature13864
- Received
- Accepted
- Published online
Site-specific gene addition can allow stable transgene expression for gene therapy. When possible, this is preferred over the use of promiscuously integrating vectors, which are sometimes associated with clonal expansion1 and oncogenesis2. Site-specific endonucleases that can induce high rates of targeted genome editing are finding increasing applications in biological discovery and gene therapy3. However, two safety concerns persist: endonuclease-associated adverse effects, both on-target4 and off-target5, 6; and oncogene activation caused by promoter integration, even without nucleases7. Here we perform recombinant adeno-associated virus (rAAV)-mediated promoterless gene targeting without nucleases and demonstrate amelioration of the bleeding diathesis in haemophilia B mice. In particular, we target a promoterless human coagulation factor IX (F9) gene to the liver-expressed mouse albumin (Alb) locus. F9 is targeted, along with a preceding 2A-peptide coding sequence, to be integrated just upstream to the Alb stop codon. While F9 is fused to Alb at the DNA and RNA levels, two separate proteins are synthesized by way of ribosomal skipping. Thus, F9 expression is linked to robust hepatic albumin expression without disrupting it. We injected an AAV8-F9 vector into neonatal and adult mice and achieved on-target integration into ~0.5% of the albumin alleles in hepatocytes. We established that F9 was produced only from on-target integration, and ribosomal skipping was highly efficient. Stable F9 plasma levels at 7–20% of normal were obtained, and treated F9-deficient mice had normal coagulation times. In conclusion, transgene integration as a 2A-fusion to a highly expressed endogenous gene may obviate the requirement for nucleases and/or vector-borne promoters. This method may allow for safe and efficacious gene targeting in both infants and adults by greatly diminishing off-target effects while still providing therapeutic levels of expression from integration.
At a glance
Figures
-
Figure 1: Vector design and experimental scheme. a, The rAAV8 vector encodes a codon-optimized human F9 cDNA preceded by a 2A-peptide coding sequence and flanked by homology arms spanning the mouse Alb stop codon. Length of the 5′ and 3′ arms are 1.3 and 1.4 kb, respectively. After integration by homologous recombination, Alb and F9 are fused at the DNA and RNA levels, but two separate proteins are produced as the result of ribosomal skipping. b, With respect to the Alb homology arms, the AAV inverse control has F9 inverted along with the 2A-peptide coding sequence, the adjacent Alb exon and the preceding splice junction. Thin white lines denote Alb introns; dark grey boxes denote Alb exons; white boxes denote P2A; white arrows denote F9 transgene; light grey boxes denote extragenic DNA. P, proline.
-
Figure 2: Human F9 expression and activity in injected mice. a, Plasma F9 measured by ELISA following intraperitoneal injections of 2-day-old B6 mice with 2.5 × 1011 vector genomes per mouse of either the AAV8-F9 experimental construct (n = 6) or inverse control (n = 3). The limit of detection was 20 ng ml−1. PH, partial hepatectomy. Error bars represent s.d. Dashed lines denote 5% and 20% of normal F9 levels. b, Plasma F9 measured by ELISA after tail vein injections of 9-week-old female B6 mice with 1 × 1012 vector genomes per mouse of the AAV8-F9 experimental construct (n = 7), or inverse control (n = 3), or a hydrodynamic injection of 30 μg plasmid (3.5 × 1012 copy number) coding for the F9 construct in the ‘correct’ orientation (n = 3). The limit of detection was 20 ng ml−1. Error bars and dashed lines as in a. c, Plasma F9 measured by ELISA following tail vein injections of 9-week-old female B6 mice with the designated vector dose of AAV8-F9 experimental construct (n = 4 for each dose group). Error bars represent s.d. d, Measurement of coagulation efficiency by activated partial thromboplastin time (aPTT) 2 weeks after tail vein injections of AAV8-F9 at 1 × 1012 vector genomes per mouse (n = 5). KO, knockout. Error bars represent s.d. e, Western blot analysis for F9 in liver samples from mice injected with the AAV8-F9 construct or inverse control. The expected size of human F9 is 55 kilodaltons (kDa).
-
Figure 3: Rate of Alb targeting at the DNA and RNA levels. a, Assessment of on-target integration rate begins using linear amplification with biotinylated primer 1 (black), annealing to the genomic locus but not to the vector. Linear amplicons are then bound to streptavidinylated beads and washed to exclude episomal vectors. Subsequent second-strand DNA synthesis with random primers was followed by CviQI restriction digestion. A compatible linker is then ligated, followed by two rounds of nested PCR (primers 2–3 in blue, and then primers 4–5 in red). CviQI cleaves at the same distance from the homology border in both targeted and wild-type alleles, thus allowing for unbiased amplification. The amplicons of the second nested PCR then serve as a template for qPCR assays with either primers 6–7 (green) or 8–9 (orange). b, For mRNA quantification, primers 10–11 or 11–12 were used to generate a cDNA for qPCR assays. Shape and fill code as in Fig. 1. c, Black bars represent the targeting rate of Alb alleles as the ratio between the abundance of the DNA template amplified by primers 6–7 to the abundance of the DNA template amplified by primers 8–9, corrected by a factor of 0.7 to account for hepatocyte frequency. Grey bars represent the expression rate of targeted Alb alleles as the ratio between the abundance of the cDNA template amplified by primers 10–11 to the abundance of the cDNA template amplified by primers 11–12. n = 3 for each group, error bars represent s.d.
-
Figure 4: Specificity of F9 expression. a, cDNA, produced from reverse transcription with a poly-dT primer, served as a template for a qPCR assay with either primers 13–14 or 14–15. b, Bars represent the rate of Alb-F9 mRNAs to total F9-containing mRNAs as the ratio between the abundance of the cDNA template amplified by primers 13–14 to the abundance of the cDNA template amplified by primers 14–15. n = 3 for each group, error bars represent s.d. c, Northern blot analysis of liver samples with a probe against P2A. The lower nonspecific signal corresponds in size to 18S rRNA. d, Western blot analysis of P2A from liver samples of mice injected with the AAV8-F9 construct or inverse control. P2A is expected to be fused to albumin (66.5 kDa).
-
Extended Data Fig. 1: Human F9 liver immunohistochemistry. From top to bottom, panels show human F9 staining (red) with 4′,6-diamidino-2-phenylindole (DAPI) nuclear counterstain (blue) in positive control human liver, negative control untreated mouse liver, and two sets of representative stains from mice treated as neonates or adults with AAV8-F9. Original magnification, ×200.
-
Extended Data Fig. 2: Scheme of targeting rate assessment. Assessment of on-target integration rate begins using linear amplification with biotinylated primer 1 (black), annealing to the genomic locus but not to the vector (step 1). Linear amplicons are then bound to streptavidinylated beads and washed to exclude episomal vectors (step 2). Subsequent second-strand DNA synthesis with random primers (step 3) was followed by CviQI restriction digestion (step 4). A compatible linker is then ligated (step 5) followed by two rounds of nested PCR amplifications (primers 2–3 in blue (step 6), and then primers 4–5 in red (step 7)). CviQI cleaves at the same distance from the homology border in both targeted and wild-type alleles, thus allowing for unbiased amplification. The amplicons of the second nested PCR then serve as a template for qPCR assays with either primers 6–7 (green) or 8–9 (orange) (step 8).
-
Extended Data Fig. 3: Standard curves for targeting rate assessment by qPCR. -
Extended Data Fig. 4: Toxicity assessment by ALT measurement. Alanine transaminase levels (ALT) were evaluated 7 days after injection in mice injected with AAV8 coding for our experimental vector (1 × 1012) or a negative control coding for a known non-toxic cassette (1 × 1012 of H1 promoter-driven shRNA), or a positive control coding for a known toxic cassette (5 × 1011 of U6 promoter-driven shRNA). Data represent mean of two measurements of four independent mice for each groups. The statistical significance is defined here as having P < 0.05 in a one-tailed t-test between samples of different variance.
-
Extended Data Fig. 5: Vector copy number. Vector copy number assessed by qPCR using primers 8 and 9 (Fig. 3). n = 7 for mice injected as adults; n = 6 for mice injected as neonates and analysed before or after partial hepatectomy (PH). Error bars represent s.d.